mAb-话题@MedSci

#mAb#

1302篇内容 | 2327人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1912574, encodeId=6fe119125e454, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=EMA接受Astellas / Seagen的enfortumab vedotin的销售授权申请（MAA）, objectType=article, longId=209073, objectId=c97e2090e362, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c97e2090e362, replyNumber=0, likeNumber=57, createdTime=2021-12-10, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c97e2090e362, moduleTitle=EMA接受Astellas / Seagen的enfortumab vedotin的销售授权申请（MAA）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c97e2090e362)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912645, encodeId=29df19126458e, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=NEJM：Bimekizumab与阿达木单抗对斑块状银屑病的疗效比较，王者诞生？, objectType=article, longId=213912, objectId=0cae21391291, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0cae21391291, replyNumber=0, likeNumber=76, createdTime=2021-09-30, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0cae21391291, moduleTitle=NEJM：Bimekizumab与阿达木单抗对斑块状银屑病的疗效比较，王者诞生？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0cae21391291)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912444, encodeId=0ca8191244415, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=FDA授予Disitamab Vedotin（RC48）治疗泌尿上皮细胞癌“突破性疗法称号”, objectType=article, longId=201251, objectId=a8de201251f5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a8de201251f5, replyNumber=0, likeNumber=55, createdTime=2020-12-02, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a8de201251f5, moduleTitle=FDA授予Disitamab Vedotin（RC48）治疗泌尿上皮细胞癌“突破性疗法称号”, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a8de201251f5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912490, encodeId=4ef61912490f1, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Lancet pheumatol：皮下予以Anifrolumab治疗系统性红斑狼疮, objectType=article, longId=203702, objectId=a1f2203e02df, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a1f2203e02df, replyNumber=0, likeNumber=81, createdTime=2021-05-26, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a1f2203e02df, moduleTitle=Lancet pheumatol：皮下予以Anifrolumab治疗系统性红斑狼疮, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a1f2203e02df)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912516, encodeId=ed6c1912516f3, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=JNNP:Erenumab对发作性偏头痛患者功能结果的影响, objectType=article, longId=205811, objectId=eb4e205811ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eb4e205811ce, replyNumber=0, likeNumber=51, createdTime=2021-07-24, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eb4e205811ce, moduleTitle=JNNP:Erenumab对发作性偏头痛患者功能结果的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eb4e205811ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912632, encodeId=45141912632fe, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=勃林格殷格翰同类首创在研免疫新药Spesolimab获得CDE突破性治疗药物认定, objectType=article, longId=213247, objectId=3f8321324e7a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3f8321324e7a, replyNumber=0, likeNumber=69, createdTime=2022-05-21, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3f8321324e7a, moduleTitle=勃林格殷格翰同类首创在研免疫新药Spesolimab获得CDE突破性治疗药物认定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3f8321324e7a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912621, encodeId=53261912621e5, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=JCO：阿替利珠单抗（Atezolizumab）+贝伐珠单抗+化疗在初始诊断III或IV期卵巢癌中的疗效和安全性：安慰剂对照随机III期研究(IMagyn050/GOG 3015/ENGOT-OV39), objectType=article, longId=212511, objectId=4d8b21251198, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4d8b21251198, replyNumber=0, likeNumber=123, createdTime=2021-12-19, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4d8b21251198, moduleTitle=JCO：阿替利珠单抗（Atezolizumab）+贝伐珠单抗+化疗在初始诊断III或IV期卵巢癌中的疗效和安全性：安慰剂对照随机III期研究(IMagyn050/GOG 3015/ENGOT-OV39), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4d8b21251198)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912448, encodeId=1524191244899, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Future Oncol：Pembrolizumab在肺癌中的治疗效果, objectType=article, longId=201423, objectId=b60d20142341, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b60d20142341, replyNumber=0, likeNumber=0, createdTime=2021-02-23, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b60d20142341, moduleTitle=Future Oncol：Pembrolizumab在肺癌中的治疗效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b60d20142341)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912653, encodeId=412a1912653c3, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=JAMA子刊：FDA为什么会加速批准阿尔茨海默病新药Aducanumab？, objectType=article, longId=214324, objectId=bc812143240c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bc812143240c, replyNumber=0, likeNumber=105, createdTime=2021-07-25, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bc812143240c, moduleTitle=JAMA子刊：FDA为什么会加速批准阿尔茨海默病新药Aducanumab？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bc812143240c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912646, encodeId=131a191264619, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Alvotech启动Stelara® (Ustekinumab)拟议生物仿制药AVT04的临床研究, objectType=article, longId=213917, objectId=365621391e66, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=365621391e66, replyNumber=0, likeNumber=109, createdTime=2021-08-20, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=365621391e66, moduleTitle=Alvotech启动Stelara® (Ustekinumab)拟议生物仿制药AVT04的临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=365621391e66)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912573, encodeId=42cf19125e336, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=JNNP:Erenumab对发作性偏头痛患者功能结果的影响：LIBERTY研究的结果, objectType=article, longId=209017, objectId=5acf20901eaa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5acf20901eaa, replyNumber=0, likeNumber=64, createdTime=2021-12-19, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5acf20901eaa, moduleTitle=JNNP:Erenumab对发作性偏头痛患者功能结果的影响：LIBERTY研究的结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5acf20901eaa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912601, encodeId=7925191260199, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Lancet oncol：Loncastuximab tesirine可有效治疗复发性/难治性DLBCL！, objectType=article, longId=211283, objectId=6e722112837b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6e722112837b, replyNumber=0, likeNumber=0, createdTime=2022-04-18, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6e722112837b, moduleTitle=Lancet oncol：Loncastuximab tesirine可有效治疗复发性/难治性DLBCL！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6e722112837b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912470, encodeId=013219124e01a, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=头对头3期临床证实：抗IL-17单抗Bimekizumab治疗中度至重度银屑病优于TNF单抗修美乐, objectType=article, longId=202790, objectId=00a7202e904b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=00a7202e904b, replyNumber=0, likeNumber=69, createdTime=2021-09-16, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=00a7202e904b, moduleTitle=头对头3期临床证实：抗IL-17单抗Bimekizumab治疗中度至重度银屑病优于TNF单抗修美乐, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=00a7202e904b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912439, encodeId=4a071912439a8, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Rozanolixizumab治疗原发性免疫性血小板减少症：II期研究取得积极进展, objectType=article, longId=200483, objectId=a181200483f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a181200483f7, replyNumber=0, likeNumber=75, createdTime=2021-02-15, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a181200483f7, moduleTitle=Rozanolixizumab治疗原发性免疫性血小板减少症：II期研究取得积极进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a181200483f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912598, encodeId=830519125987a, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=J Thorac Oncol：不可切除III期NSCLC放化疗后无进展患者德瓦鲁单抗（durvalumab）维持治疗4年生存分析结果：来自PACIFIC结果更新, objectType=article, longId=211196, objectId=ec7921119623, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ec7921119623, replyNumber=0, likeNumber=63, createdTime=2022-02-07, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ec7921119623, moduleTitle=J Thorac Oncol：不可切除III期NSCLC放化疗后无进展患者德瓦鲁单抗（durvalumab）维持治疗4年生存分析结果：来自PACIFIC结果更新, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ec7921119623)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912479, encodeId=2f8619124e987, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=诺华IL-1β单抗canakinumab治疗新冠COVID-19：未能提高生存率, objectType=article, longId=203185, objectId=8a9e203185f0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8a9e203185f0, replyNumber=0, likeNumber=61, createdTime=2021-03-22, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8a9e203185f0, moduleTitle=诺华IL-1β单抗canakinumab治疗新冠COVID-19：未能提高生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8a9e203185f0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912608, encodeId=245719126086c, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Lancet：Ziltivekimab可有效降低高动脉粥样硬化风险个体的炎症标志物, objectType=article, longId=211545, objectId=56bd211545ef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=56bd211545ef, replyNumber=0, likeNumber=89, createdTime=2021-11-07, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=56bd211545ef, moduleTitle=Lancet：Ziltivekimab可有效降低高动脉粥样硬化风险个体的炎症标志物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=56bd211545ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912563, encodeId=eb30191256363, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=BLOOD：好消息！ISAtuximab 联合地塞米松治疗复发/难治性多发性骨髓瘤可提高ORR, objectType=article, longId=207913, objectId=49ca20e9132b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=49ca20e9132b, replyNumber=0, likeNumber=52, createdTime=2021-05-17, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=49ca20e9132b, moduleTitle=BLOOD：好消息！ISAtuximab 联合地塞米松治疗复发/难治性多发性骨髓瘤可提高ORR, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=49ca20e9132b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912640, encodeId=699a19126402a, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Ann Oncol: atezolizumab联合白蛋白结合型紫杉醇一线治疗不可切除、局部晚期或转移性三阴性乳腺癌的疗效: IMpassion130最终总生存分析, objectType=article, longId=213736, objectId=41a6213e36ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=41a6213e36ec, replyNumber=0, likeNumber=94, createdTime=2022-03-19, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=41a6213e36ec, moduleTitle=Ann Oncol: atezolizumab联合白蛋白结合型紫杉醇一线治疗不可切除、局部晚期或转移性三阴性乳腺癌的疗效: IMpassion130最终总生存分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=41a6213e36ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912491, encodeId=50db1912491e7, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=欧盟委员会批准了TREMFYA®（guselkumab）治疗活动性银屑病关节炎（PsA）, objectType=article, longId=203779, objectId=0bb5203e7985, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0bb5203e7985, replyNumber=0, likeNumber=62, createdTime=2021-04-24, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0bb5203e7985, moduleTitle=欧盟委员会批准了TREMFYA®（guselkumab）治疗活动性银屑病关节炎（PsA）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0bb5203e7985)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

mAb

2020-05-29

snf701207 (审核中...)

前往app查看评论内容

#mAb#

EMA接受Astellas / Seagen的enfortumab vedotin的销售授权申请（MAA）

2021-12-10

snf701207 (审核中...)

前往app查看评论内容

#mAb#

NEJM：Bimekizumab与阿达木单抗对斑块状银屑病的疗效比较，王者诞生？

2021-09-30

snf701207 (审核中...)

前往app查看评论内容

#mAb#

FDA授予Disitamab Vedotin（RC48）治疗泌尿上皮细胞癌“突破性疗法称号”

2020-12-02

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Lancet pheumatol：皮下予以Anifrolumab治疗系统性红斑狼疮

2021-05-26

snf701207 (审核中...)

前往app查看评论内容

#mAb#

JNNP:Erenumab对发作性偏头痛患者功能结果的影响

2021-07-24

snf701207 (审核中...)

前往app查看评论内容

#mAb#

勃林格殷格翰同类首创在研免疫新药Spesolimab获得CDE突破性治疗药物认定

2022-05-21

snf701207 (审核中...)

前往app查看评论内容

#mAb#

JCO：阿替利珠单抗（Atezolizumab）+贝伐珠单抗+化疗在初始诊断III或IV期卵巢癌中的疗效和安全性：安慰剂对照随机III期研究(IMagyn050/GOG 3015/ENGOT-OV39)

2021-12-19

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Future Oncol：Pembrolizumab在肺癌中的治疗效果

2021-02-23

snf701207 (审核中...)

前往app查看评论内容

#mAb#

JAMA子刊：FDA为什么会加速批准阿尔茨海默病新药Aducanumab？

2021-07-25

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Alvotech启动Stelara® (Ustekinumab)拟议生物仿制药AVT04的临床研究

2021-08-20

snf701207 (审核中...)

前往app查看评论内容

#mAb#

JNNP:Erenumab对发作性偏头痛患者功能结果的影响：LIBERTY研究的结果

2021-12-19

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Lancet oncol：Loncastuximab tesirine可有效治疗复发性/难治性DLBCL！

2022-04-18

snf701207 (审核中...)

前往app查看评论内容

#mAb#

头对头3期临床证实：抗IL-17单抗Bimekizumab治疗中度至重度银屑病优于TNF单抗修美乐

2021-09-16

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Rozanolixizumab治疗原发性免疫性血小板减少症：II期研究取得积极进展

2021-02-15

snf701207 (审核中...)

前往app查看评论内容

#mAb#

J Thorac Oncol：不可切除III期NSCLC放化疗后无进展患者德瓦鲁单抗（durvalumab）维持治疗4年生存分析结果：来自PACIFIC结果更新

2022-02-07

snf701207 (审核中...)

前往app查看评论内容

#mAb#

诺华IL-1β单抗canakinumab治疗新冠COVID-19：未能提高生存率

2021-03-22

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Lancet：Ziltivekimab可有效降低高动脉粥样硬化风险个体的炎症标志物

2021-11-07

snf701207 (审核中...)

前往app查看评论内容

#mAb#

BLOOD：好消息！ISAtuximab 联合地塞米松治疗复发/难治性多发性骨髓瘤可提高ORR

2021-05-17

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Ann Oncol: atezolizumab联合白蛋白结合型紫杉醇一线治疗不可切除、局部晚期或转移性三阴性乳腺癌的疗效: IMpassion130最终总生存分析

2022-03-19

snf701207 (审核中...)

前往app查看评论内容

#mAb#

欧盟委员会批准了TREMFYA®（guselkumab）治疗活动性银屑病关节炎（PsA）

2021-04-24

科室
- - 订阅+
  - 更多科室
工具
服务